Panel rejects psychedelic drug MDMA as a PTSD treatment in possible setback for advocates
People with post-traumatic stress disorder (PTSD) may soon have a new treatment option: MDMA, the chemical found in ecstasy. In August, the Food and Drug Administration plans to decide whether MDMA-assisted therapy for PTSD will be approved for market based on years of research.
32 across the spectrum · tap a section to jump
The story so far
2 developments- May 31, 2024Psychedelic drug MDMA faces questions as FDA considers approval for PTSD
- Jun 4, 2024Federal health advisory panel rejects psychedelic drug MDMA as a PTSD treatment
Who covered each development
No new developments
Quiet for 847 daysLast development · Jun 4, 2024 — Federal health advisory panel rejects psychedelic drug MDMA as a PTSD treatment
Left
9 viewpointsFDA advisors reject MDMA therapy for PTSD, amid concerns over research
Panel rejects psychedelic drug MDMA as a PTSD treatment in setback for advocates
Center
20 viewpointsRight
3 viewpointsFDA advisers overwhelmingly oppose approval of MDMA as a psychotherapeutic catalyst
Panel rejects psychedelic drug MDMA as a PTSD treatment in possible setback for advocates
Psychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medication